Relationships between serum lipid composition and acetylator status as markers of energy metabolism in women with coronary heart disease, metabolic syndrome, and type 2 diabetes mellitus

Matveeva S.A.

doi:https://doi.org/

Matveeva S.A.

Mediko-psikhologicheskiĭ tsentr "Sem'Ia", Riazan'

Relationships between serum lipid composition and acetylator status as markers of energy metabolism in women with coronary heart disease, metabolic syndrome, and type 2 diabetes mellitus

Authors:

Matveeva S.A.

More about the authors

Journal: Therapeutic Archive. 2013;85(12): 14‑20

Read: 1686 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Matveeva SA. Relationships between serum lipid composition and acetylator status as markers of energy metabolism in women with coronary heart disease, metabolic syndrome, and type 2 diabetes mellitus. Therapeutic Archive. 2013;85(12):14‑20. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Comparative analysis of the state of the microvasculature of the oral mucosa in persons with metabolic syndrome in the aspect of orthopedic dental rehabilitation. Stomatology. 2024;(6-2):15-22

Refralon for drug-induced cardioversion of atrial fibrillation in patients with coronary artery disease. Russian Cardiology Bulletin. 2024;(4-2):188-196

Relationship between metabolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63

Incidence of diseases of the circulatory system in the working-age population of the Ural Federal District in 2012—2022. Russian Journal of Preventive Medicine. 2025;(1):24-29

Clinical outcomes after transcatheter aortic valve implantation in patients with concomitant coronary artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):45-52

Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60

Adipocytokines as a predictor of the risk of adverse outcomes in patients with coronary heart disease and abdominal obesity after percutaneous coronary intervention. Russian Journal of Preventive Medicine. 2025;(2):38-45

The Relationship of obstructive sleep apnea with paroxysmal atrial fibrillation in women suffered coronary heart disease and arterial hypertension. Russian Journal of Preventive Medicine. 2025;(2):61-66

Clinical efficacy of high-intensity magnetic therapy and transcutaneous electrical nerve stimulation in patients with diabetes mellitus and distal polyneuropathy: a randomized study. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(1):5-11

Classical and new atherosclerosis biomarkers in elderly patients with type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2025;(3):87-95

Abstract:

Aim. To study relationships between the indicators of serum lipid composition (SLC) and the markers of acetylator (energy) status (AS) in women with coronary heart disease (CHD), stable exertional angina (SEA), metabolic syndrome (MS), type 2 diabetes mellitus (DM) (according to the data multivariate correlation analysis). Subjects and methods. One hundred and eight women aged 54.9±0.7 years with CHD, Functional Class I-III SEA, MS, and type 2 DM were examined. SLC was studied, by determining the levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), atherogenic coefficient (AC), triglyceride coefficient (TC) (TC=TG/HDL-C). AS markers, such as blood acetylation degree (BAD) and the total acetylating capacity of the body (TACB), were concurrently determined. Correlations of each individual indicator of a lipidogram (TC, TG, LDL-C, VLDL-C, HDL-C, AC, and TC) and an AS marker (BAD, TACB) were analyzed in tandem. Results. Examination of the relationships between SLC the indicators and AS markers in women with CHD, MS, and type 2 DM could establish that the values of a variant, ≤10th and >90th percentiles of SLC indicators (TC, TG, LDL-C, VLDL-C, HDL-C, AC, and TC) showed a significant strong direct (positive) relationship to those of the variant, ≤10th and >90th percentiles of AS markers (BAD, TACB). A significant inverse (negative) correlation was found between the values of the ≤10th percentile of SLC indicators (TC, TG, LDL-C, VLDL-C, HDL-C, AC, and TC) and those of >90th percentile of AS markers (BAD, TACB), as well as between the values of >90th percentile of SLC indicators (TC, TG, LDL-C, VLDL-C, HDL-C, AC, and TC) and those of ≤10th percentile of AS markers (BAD, TACB). Conclusion. The heterogeneity in the association was ascertained between the values of ≤10th percentile/>90th percentile/variant of SLC and AS markers. The genetic polymorphism of AS - the phenotypes of slow/fast/ intermediate acetylators (a three modal distribution) was stated. Knowledge of the patterns of relationships between BAD/AS and the polymorphism of the phenotypes of slow/fast/intermediate acetylators may contribute to the formation of differentiated groups at risk for cardiovascular and concomitant diseases and to adequate prevention and treatment.

Keywords:

lipid metabolism

acetylator (energy) status

coronary heart disease

metabolic syndrome

type 2 diabetes mellitus

Authors:

Matveeva S.A.

Mediko-psikhologicheskiĭ tsentr "Sem'Ia", Riazan'

Close metadata

References:

Diagnostika i korrektsiya narushenii lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza. Rossiiskie rekomendatsii. V peresmotr. M 2012; 29.
ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-1818.
The European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoprotein and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-1361.
Donahoe S.M., Stewart G.C., McCabe C.H. et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765-775.
Mills E.J., Rachlis B., Wu P. et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65000 patients. J Am Coll Cardiol 2008; 52: 1769-1781.
Goldfine A.B., Fonseca V. Management of diabetes mellitus in patients with cardiovascular disease in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) Trial. Circulation 2010; 121: 2447-2449.
Natsional'nye klinicheskie rekomendatsii "Diagnostika i lechenie metabolicheskogo sindroma" (vtoroi peresmotr). Kardiovask ter i prof 2009; 8 (6) (prilozhe-nie 2).
Liu J., Grundy S.M., Wang W. et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007; 153: 552-558.
Lundgren J.D., Battegay M., Behrens G. et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIVMed 2008; 9: 72-81.
Ordovas J.M. Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. Am J Clin Nutr 2009; 89: 1509S-1517S.
Mooradian A.D., Haas M.J., Wong N.C. The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 2006; 27: 2-16.
Rosenson R.S., Brewer H.B., Davidson W.S. Jr. et al. Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport. Circulation 2012; 125: 1905-1919.
Wang Q., Zhang Y., Yang C. et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010; 327 (5968): 1004-1007.
Hirschey M.D., Shimazu T., Goetzman E. et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010; 464 (1): 121-125.
Bannister A.J., Miska E.A. Regulation of gene expression by transcription factor acetylation. Cellular and Molecular Life Sciences 2000; 57 (8-9): 1184-1192.
Fatland B.L. Reverse genetic characterization of cytosolic acetyl-CoA generation by ATP-citrate lyase in arabidopsis. The Plant Cell Online 2005; 17: 182.
Vatsis K.P., Weber W.W., Bell D.A. et al. Nomenclature for Nacetyltransferases. Pharmacogenetics 1995; 5: 1-17.
Vatsis K.P., Weber W.W. Human N-acetyltransferase. In: Kauffman F.C. (ed.) Conjugation - deconjugation reaction in drug metabolism and toxicity. handbook of experimental pharmacology. Heidelberg: Springer-Verlag 1994: 109-130.
Kholodov L.E., Yakovlev V.P. Klinicheskaya farmakokinetika. M: Meditsina 1985.
Diagnostika i lechenie stabil'noi stenokardii: natsional'nye klinicheskie rekomendatsii - 2008. Kardiovask ter i prof 2008; 7 (6): Prilozhenie 4.
Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii. IV peresmotr. Sistemnye gipertenzii 2010; 3: 34.
Alberti K.G., Zimmet P.Z. Definition, diagnosis, and classification of diabetes mellitus and its complications, part I: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15 (7): 539-553.
WHO. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999; 23 (1): 4-16.
Global Guideline for type 2 diabetes. International Diabetes Federation; 2005.
International Diabetes Federation. Diabetes Atlas. 5th ed. Brussels: International Diabetes Federation. 2011; 137.
Balabolkin M.I. Diabetologiya. M 2000.
Timofeeva A.M. Metod opredeleniya sul'famidov. Farmakol i toksikol 1944; 2: 61-63.
Polukhina L.M. Metody izucheniya vsasyvaniya, raspredeleniya v organizme i vydeleniya khimioterapevticheskikh sredstv. Metody eksperimental'noi khimioterapii. M 1971.
Barter P., Gotto A.M., La Rosa J.C. et al. HDL cholesterol, very low levels of LDL Cholesterol and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
Coodley G.O., Jorgensen M., Kirschenbaum J. et al. Sholesterol in adults: a prospective, community-based practice initiative. Am J Med 2008; 121: 604-610.
Mottillo S., Filion K.B., Genest J. et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
Adiels M., Olofsson S.-O., Taskinen M.-R. et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225-1236.
Cefalu W.T. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood). 2001; 226 (1): 13-26.
Leclercq I.A., Da Silva Morais A., Schroyen B. et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007; 47 (1): 142-156.
Demidova T.Yu. Ozhirenie i insulinorezistentnost'. Trudnyi patsient 2006; 7: 25-28.
Zechner R., Strauss J.G., Haemmerle G. et al. Lipolysis: pathway under construction. Curr Opin Lipidol 2005; 16: 333-340.
Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001; 2 (4): 282-286.
Elmhurst College. Lipogenesis. Retrieved 2007; 12: 22.
Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
Kantor P.F., Dyck J.R., Lopaschuk G.D. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci 1999; 318: 3-4.
Lopaschuk G.D., Ussher J.R.L., Folmes C.D. et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010; 90 (1): 207-258.
Rinaldo P., Matern D. Disorders of fatty acid transport and mitochondrial oxidation: challenges and dilemmas of metabolic evaluation. Genetic Med 2000; 2 (6): 338-344.
Hirschey D., Shimazu T., Goetzman E. et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010; 464 (1): 121-125.